The protein alpha-synuclein aggregates are constituents of Lewy bodies, a histological hallmark of the synuceinopathies Parkinson's disease, Lewy body dementia and multiple system atrophy.
Elucidating the forms alpha-synuclein molecules adopt upon staking within aggregates is key for the design of ligands targeting those aggregates. Such ligands could attach along or at the ends of the resulting fibrils and affect their surface properties or their ability to elongate and thus limit the pathological processes involved in synucleinopathies.
Partner CNRS within a collaborative study with experts in Cryo-Electron microscopy recently determined a new structure for alpha-synuclein fibrils, down to an atomic level. Those fibrils, when injected into rodent models, cause the development of symptoms characteristic of Parkinson's disease.Read more
IMPRiND partner CNRS research shows diagnostic & therapeutic potential in the prion-like propagation of fibrillar aSYN, as they can facilitate the design of ligands that specifically bind & distinguish between fibrillar polymorphs. Read the publication.
IMI is organising a series of online live sessions on IMI’s Impact, where key actors will explore the challenges and demonstrate how IMI contributed. As part of this event a IMI impact on dementia Event will be organised on 15 June 2021, 2:00 - 4:00 CEST.
The event comprises of a series of presentations including a talk on NEURONET by our Project Coordinator Carlos Diaz. To learn more about the event
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.
The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.